Docs concerned for the use of Favipiravir for COVID in India
By MYBRANDBOOK
Favipiravir, an antiviral drug for the treatment of mild-to-moderate COVID-19 cases, was launched recently by Glenmark Pharmaceuticals. According to reports, the drug has been launched after it received approval from the Drug Controller General of India to manufacture and market the medicine.
The antiviral drug Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It works by inhibiting viral replication and reducing the viral load in a patient. It is an experimental medicine being repurposed for COVID-19.
According to Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals the approval has come at a time when cases in India are spiralling, putting tremendous pressure on our healthcare system.
The drug FabiFlu will be available as a prescription-based medication for Rs 103 per tablet, with the recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.
The drug is not recommended in patients with severe renal, hepatic impairment, and in pregnant and lactating women.
Glenmark has claimed that Favipiravir shows clinical improvements of up to 88% in COVID-19 disease, with a rapid reduction in viral load by 4 days.
Favipiravir is being studied in at least 18 trials around the world as a potential treatment for COVID-19. Earlier last month, Glenmark also announced that it is conducting another clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India.
But according to doctors there is insufficient evidence in favour of the medicine. A large portion of doctors don’t feel there is any real requirement of the medicine for mild attacks. They feel there is so much panic and fear around the disease that they will be forced to arrange for the medicine even if they have no funds - when in reality, a mild COVID case may recover either without medication, or with medicines costing no more than Rs 10.
Nazara and ONDC set to transform in-game monetization with ‘
Nazara Technologies has teamed up with the Open Network for Digital Comme...
Jio Platforms and NICSI to offer cloud services to government
In a collaborative initiative, the National Informatics Centre Services In...
BSNL awards ₹5,000 Cr Project to RVNL-Led Consortium
A syndicate led by Rail Vikas Nigam Limited (abbreviated as RVNL), along wi...
Pinterest tracks users without consent, alleges complaint
A recent complaint alleges that Pinterest, the popular image-sharing platf...
BPE INDIA PVT. LTD.
TALLY SOLUTIONS PVT. LTD.
INFOSYS TECHNOLOGIES PVT. LTD.
PDRL - Passenger Drone Research Pvt. Ltd.
Icons Of India : NIKHIL RATHI
Co-founder & CEO of Web Werks, a global leader in Data Centers and Clo...
Icons Of India : Dilip Asbe
At present, Dilip Asbe is heading National Payments Corporation of Ind...
Icons Of India : NATARAJAN CHANDRASEKARAN
Natarajan Chandrasekaran (Chandra) is the Chairman of Tata Sons, the h...
IOCL - Indian Oil Corporation Ltd.
IOCL is India’s largest oil refining and marketing company ...
IREDA - Indian Renewable Energy Development Agency Limited
IREDA is a specialized financial institution in India that facilitates...
DRDO - Defence Research and Development Organisation
DRDO responsible for the development of technology for use by the mili...
Indian Tech Talent Excelling The Tech World - REVATHI ADVAITHI, CEO- Flex
Revathi Advaithi, the CEO of Flex, is a dynamic leader driving growth ...
Indian Tech Talent Excelling The Tech World - AJAY BANGA, President - World Bank
Ajay Banga is an Indian-born American business executive who currently...
Indian Tech Talent Excelling The Tech World - Steve Sanghi, Executive Chair, Microchip
Steve Sanghi, the Executive Chair of Microchip Technology, has been a ...